-
Sector Analysis
NewOvarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. Ovarian Cancer is one of the most lethal gynecological cancers worldwide. Despite being...
-
Sector Analysis
Spinal Non-Fusion Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033
Spinal Non-Fusion Market Report Overview The spinal non-fusion market size was $884.8 million in 2023. The market is expected to grow at a CAGR of more than 5% during 2023-2033. Spinal non-fusion surgery is performed to treat spinal instability, degenerative disc disorder, and spinal stenosis while preserving the spine's normal motion, load bearing, and shock absorption capacity. Spinal non-fusion surgery also provides pain relief without major anatomical removal. Spinal Non-Fusion Market Outlook, 2023-2033 ($ Million) Buy the Full Report for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zilovertamab Vedotin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zilovertamab Vedotin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zilovertamab Vedotin in Triple-Negative Breast Cancer (TNBC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pentosan Polysulfate Sodium in Alphavirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pentosan Polysulfate Sodium in Alphavirus Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pentosan Polysulfate Sodium in Alphavirus Infections Drug Details: Pentosan polysulfate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pentosan Polysulfate Sodium in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pentosan Polysulfate Sodium in Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pentosan Polysulfate Sodium in Mucopolysaccharidosis...
-
Product Insights
Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Edema - Drugs In Development, 2023’, provides an overview of the Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Seasonal Allergic Rhinitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Seasonal Allergic Rhinitis - Drugs In Development, 2023’, provides an overview of the Seasonal Allergic Rhinitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seasonal Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Epidermolysis Bullosa – Drugs In Development, 2023
Global Markets Direct’s, ‘Epidermolysis Bullosa - Drugs In Development, 2023’, provides an overview of the Epidermolysis Bullosa pipeline landscape. The report provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Chikungunya Fever – Drugs In Development, 2023
Global Markets Direct’s, ‘Chikungunya Fever - Drugs In Development, 2023’, provides an overview of the Chikungunya Fever pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chikungunya Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...